Calocurb vs Ozempic: one supplement trial vs a drug label

Calocurb is a dietary supplement, a bitter hop extract, whose weight-loss evidence is one 24-week, 150-person, placebo-controlled trial: 4.3% of body weight lost against 0.5% on placebo. Ozempic is an FDA-approved prescription semaglutide injection indicated for adults with type 2 diabetes, carrying a boxed warning for thyroid C-cell tumours.

Updated 6 November 2026: the score is removed; this is now an assessment of published documents.

That is the whole of “Calocurb vs Ozempic”. The pages at the top of that search, as we read them, are sponsored or shop copy and print neither product’s regulatory standing.

On 20 September 2026 this desk read the C4 paper in Obesity Pillars, the Ozempic label on DailyMed and the FDA’s March 2024 Wegovy release.

Calocurb vs Ozempic: what is each product, legally?

Calocurb is sold as a dietary supplement; the trial paper lists “Dietary supplement” among its keywords, and in the material we read no regulator’s approval sits beside the name. The capsule is Amarasate, a hop extract.

Ozempic’s label carries “Initial U.S. Approval: 2017”, was updated on 1 June 2026, and opens with a boxed warning headed “Risk of thyroid C-cell tumors”. Its indications, as read, are all for adults with type 2 diabetes, starting with glycaemic control; the block lists no weight-management use.

What did each trial measure?

Different durations; we set them side by side, not divided.

The Wegovy trial counted heart attacks, strokes and deaths, not weight; we did not read the Wegovy label this run, so we print no Wegovy weight-loss figure. This run’s read of the C4 paper did not reach its funding statement; our review of the C4 trial recorded from a trade report that Calocurb Ltd paid. The dropouts are in the side-effects piece; Ozempic’s commonest label reactions are nausea, vomiting, diarrhoea, abdominal pain and constipation.

Is Ozempic the weight-loss product?

Not on its label. The semaglutide product the FDA calls “the first weight loss medication” in its 2024 release is Wegovy, for adults with obesity or overweight. Our piece on GLP-1 marketing language traces how that vocabulary reached supplement labels; Calocurb’s own site calls the capsule a “natural GLP-1 activator,” a description, not a brand name.

Pros and cons

Our assessment

This is an assessment of published documents, not of using either product: one 24-week trial of 150 people set against an FDA-reviewed label, and a footer disclaimer against a boxed warning, so not a like-for-like comparison.

Documents read

Read on 6 November 2026:

• Ozempic label, DailyMed: Initial U.S. Approval 2017; boxed warning on thyroid C-cell tumors; indications all for adults with type 2 diabetes; 0.25 to 2 mg weekly; severe gastrointestinal reactions added 10/2025.
• FDA release, Wegovy cardiovascular indication, 8 March 2024: Trial randomised over 17,600; major cardiovascular events in 6.5% on Wegovy vs 8% on placebo; Wegovy called the first weight loss medication also approved for cardiovascular risk.
• C4 trial paper (PMC): Keywords include Dietary supplement; 150 randomised, 128 completed.

Frequently asked questions

Is Calocurb the same as Ozempic?

No. Calocurb is a bitter hop extract capsule sold as a dietary supplement. Ozempic is semaglutide, a prescription injection with FDA approval dating from 2017, indicated for adults with type 2 diabetes. They share a vocabulary, GLP-1, and little else: not the molecule, the regulator, the evidence or the label warnings.

Is Calocurb FDA approved?

No. Calocurb is sold as a dietary supplement, and the C4 paper’s own keywords file it under dietary supplement. Ozempic and Wegovy are FDA-approved drugs with reviewed prescribing information. Nothing this desk read this run puts any regulator’s approval, authorisation or certification beside Calocurb’s name, and we do not either.

What is the difference between Ozempic and Wegovy?

Both are semaglutide from Novo Nordisk. Ozempic’s label, updated 1 June 2026, indicates it for adults with type 2 diabetes, beginning with glycaemic control. Wegovy is the semaglutide product the FDA calls a weight loss medication, used with a reduced-calorie diet in adults with obesity or overweight. Same molecule, same boxed warning, different indications.

Calocurb is sold as a dietary supplement, and nothing here has been evaluated by the FDA or any regulator; nothing here diagnoses, treats, cures or prevents anything, and none of it is medical advice. Semaglutide is a prescription medicine; whether to take it, or a hop extract, is a question for you and a prescriber.